Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 11/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1382986 | 1.00 | KCNA5 (0.68) | KCNA5KCNH2ALDH1A1RXFP1KDM4E | |
| SCHEMBL1383316 | 1.00 | KCNA5 (0.68) | KCNA5KCNH2ALDH1A1RXFP1KDM4E | |
| SCHEMBL1385728 | 0.91 | KCNA5 (0.81) | KCNA5KCNH2ALDH1A1RXFP1KDM4E | |
| SCHEMBL5500034 | 0.91 | KCNA5 (0.81) | KCNA5KCNH2ALDH1A1RXFP1KDM4E | |
| SCHEMBL1384017 | 0.91 | KCNA5 (0.81) | KCNA5KCNH2ALDH1A1RXFP1KDM4E | |
| SCHEMBL1382414 | 0.89 | KCNA5 (0.61) | KCNA5KCNH2ALDH1A1RXFP1KDM4E | |
| SCHEMBL1385287 | 0.88 | KCNA5 (0.60) | KCNA5KCNH2ALDH1A1RXFP1KDM4E | |
| SCHEMBL6047735 | 0.88 | KCNA5 (0.59) | KCNA5KCNH2ALDH1A1RXFP1KDM4E | |
| Monoethanolamine SCHEMBL5507362 | 0.86 | KCNA5 (0.57) | KCNA5KCNH2ALDH1A1RXFP1KDM4E | |
| SCHEMBL3121513 | 0.85 | KCNA5 (0.60) | KCNA5KCNH2ALDH1A1RXFP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4794446-B2 | — | — | 2011-10-19 | — | — | JP | claimed |
| US-7691879-B2 | Isoquinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-04-06 | — | — | US | claimed |
| EP-1667979-A4 | ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2007-04-18 | — | — | EP | claimed |
| US-20060276450-A1 | Isoquinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. | 2006-12-07 | — | — | US | claimed |
| EP-1667979-A2 | ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2006-06-14 | — | — | EP | claimed |
| WO-2005030130-A2 | ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2005-04-07 | — | — | WO | claimed |
| US-7691879-B2 | Isoquinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-04-06 | — | — | US | disclosed |
| EP-1667979-A4 | ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060276450-A1 | Isoquinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. | 2006-12-07 | — | — | US | disclosed |
| EP-1667979-A2 | ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005030130-A2 | ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276450-A1 | Isoquinoline potassium channel inhibitors | KCNQ1, KCNQ2, KCNJ2 | KCNA5 15/4885KCNH2 5/4885ALDH1A1 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.